

HPTN 091 – Integrating HIV Prevention, Gender–Affirmative Medical Care, and Peer Health Navigation for Transgender Women in the Americas: A Vanguard Study
SMC Open Report – September 15, 2025
Visit Cutoff Date: September 15, 2025

Table O4i – Visit Completion Within Target Window by Visit and Site ¹

	Overall	New York – Harlem Prevention	San Francisco	Houston AIDS Research Team CRS	Philadelphia	Rio de Janeiro – Manguinhos
Total Participants Enrolled	304	48	45	51	50	110
Week 13	270/303 (89.1%)	36/48 (75.0%)	41/45 (91.1%)	40/51 (78.4%)	48/50 (96.0%)	105/109 (96.3%)
Week 26	260/298 (87.2%)	34/47 (72.3%)	41/43 (95.3%)	39/49 (79.6%)	47/50 (94.0%)	99/109 (90.8%)
Week 39	245/293 (83.6%)	34/45 (75.6%)	37/42 (88.1%)	35/48 (72.9%)	49/50 (98.0%)	90/108 (83.3%)
Week 52	238/283 (84.1%)	30/45 (66.7%)	35/40 (87.5%)	30/45 (66.7%)	47/49 (95.9%)	96/104 (92.3%)
Week 65	238/280 (85.0%)	34/45 (75.6%)	38/40 (95.0%)	33/44 (75.0%)	45/49 (91.8%)	88/102 (86.3%)
Week 78	253/278 (91.0%)	40/45 (88.9%)	38/40 (95.0%)	30/44 (68.2%)	46/50 (92.0%)	99/99 (100.0%)

¹ Visit Completion at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (target visit window has closed), plus any participants who have completed the visit prior to their window closure. The denominator will exclude any participants who are terminated or seroconverted at the time of the visit.

Source: SCHARP (Haima) – /trials/hptn/p091/analysis/atlas/code/open/t_vis_comp_tgtw_bysite.sas, SAS Version 9.4 (15SEP2025,8:15)

HPTN 091 – Integrating HIV Prevention, Gender–Affirmative Medical Care, and Peer Health Navigation for Transgender Women in the Americas: A Vanguard Study
SMC Open Report – September 15, 2025
Visit Cutoff Date: September 15, 2025

Table O4ii – Visit Completion Within Allowable Visit Window by Visit and Site ¹

	Overall	New York – Harlem Prevention	San Francisco	Houston AIDS Research Team CRS	Philadelphia	Rio de Janeiro – Manguinhos
Total Participants Enrolled	304	48	45	51	50	110
Week 13 ²	272/303 (89.8%)	36/48 (75.0%)	41/45 (91.1%)	40/51 (78.4%)	50/50 (100.0%)	105/109 (96.3%)
Week 26 ²	261/298 (87.6%)	34/47 (72.3%)	41/43 (95.3%)	39/49 (79.6%)	47/50 (94.0%)	100/109 (91.7%)
Week 39 ²	246/293 (84.0%)	34/45 (75.6%)	37/42 (88.1%)	35/48 (72.9%)	49/50 (98.0%)	91/108 (84.3%)
Week 52 ²	239/284 (84.2%)	30/45 (66.7%)	35/40 (87.5%)	30/45 (66.7%)	47/49 (95.9%)	97/105 (92.4%)
Week 65 ²	240/280 (85.7%)	34/45 (75.6%)	38/40 (95.0%)	33/44 (75.0%)	45/49 (91.8%)	90/102 (88.2%)
Week 78 ²	254/279 (91.0%)	40/45 (88.9%)	38/40 (95.0%)	30/44 (68.2%)	46/50 (92.0%)	100/100 (100.0%)

¹ Visit Completion at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (allowable visit window has closed), plus any participants who have completed the visit prior to their allowable window closure. The denominator will exclude any participants who are terminated or seroconverted at the time of the visit.

² Allowable Visit Window for week 13, 26, 39, 52, 65 and 78 is Day 77–153, 154–244, 245–336, 337–427, 428–518 and 519–Study closure respectively.

**HPTN 091 – Integrating HIV Prevention, Gender–Affirmative Medical Care, and Peer Health Navigation for Transgender Women in the Americas: A Vanguard Study
Atlas Open Report – September 15, 2025
Visit Cutoff Date: September 15, 2025**

Table O5 – Retention by Site at Three–Month Intervals ¹

	Overall	New York – Harlem Prevention	San Francisco	Houston AIDS Research Team CRS	Philadelphia	Rio de Janeiro – Manguinhos
Total Participants Enrolled	304	48	45	51	50	110
Week 13	290/290 (100.0%)	45/45 (100.0%)	42/42 (100.0%)	44/44 (100.0%)	50/50 (100.0%)	109/109 (100.0%)
Week 26	283/283 (100.0%)	43/43 (100.0%)	41/41 (100.0%)	41/41 (100.0%)	49/49 (100.0%)	109/109 (100.0%)
Week 39	277/277 (100.0%)	41/41 (100.0%)	40/40 (100.0%)	39/39 (100.0%)	49/49 (100.0%)	108/108 (100.0%)
Week 52	272/272 (100.0%)	41/41 (100.0%)	39/39 (100.0%)	37/37 (100.0%)	48/48 (100.0%)	107/107 (100.0%)
Week 65	265/265 (100.0%)	40/40 (100.0%)	39/39 (100.0%)	36/36 (100.0%)	46/46 (100.0%)	104/104 (100.0%)
Week 78	256/256 (100.0%)	40/40 (100.0%)	39/39 (100.0%)	30/30 (100.0%)	45/45 (100.0%)	102/102 (100.0%)

¹ Retention is the proportion of participants who remain in follow–up at least as long as the nominal visit time. Participants are included in the denominator if the allowable visit window has closed, plus any participants who completed the visit prior to the window closure. Allowable visit window closure for visits at months 3, 6, and 12 are enrollment date plus 153, 244, and 336 days, respectively.

Source: SCHARP (Chuwen) – /trials/hptn/p091/analysis/atlas/code/open/t_ret_bysite.sas, SAS Version 9.4 (15SEP2025,8:15)